Dr. Simeone Discusses Unmet Needs in Pancreatic Cancer

Diane Simeone, MD
Published: Tuesday, Apr 24, 2018



Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.

Simeone says that the biggest challenge in pancreatic cancer is the extreme skepticism in the community. There are many new therapies that are available, as well as exciting new clinical trials, but only about 4% of patients with pancreatic cancer go on clinical trials, says Simeone.

However, there is a big move toward understanding who is at risk for pancreatic cancer. About 10% to 13% of patients that come into the clinic with a new diagnosis of pancreatic cancer have a germline mutation, Simeone says. Identifying those risk factors are important for treatment decisions, but they also have implications for family members. The overall goal is to shift the curve in order to diagnose pancreatic cancer earlier.
SELECTED
LANGUAGE


Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.

Simeone says that the biggest challenge in pancreatic cancer is the extreme skepticism in the community. There are many new therapies that are available, as well as exciting new clinical trials, but only about 4% of patients with pancreatic cancer go on clinical trials, says Simeone.

However, there is a big move toward understanding who is at risk for pancreatic cancer. About 10% to 13% of patients that come into the clinic with a new diagnosis of pancreatic cancer have a germline mutation, Simeone says. Identifying those risk factors are important for treatment decisions, but they also have implications for family members. The overall goal is to shift the curve in order to diagnose pancreatic cancer earlier.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Navigating Treatment Decisions in Pancreatic Cancer: Key QuestionsJun 29, 20191.5
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Publication Bottom Border
Border Publication
x